Literature DB >> 15968401

Antibody profiles for the diagnosis of antiphospholipid syndrome.

Vittorio Pengo1, Alessandra Biasiolo, Cinzia Pegoraro, Umberto Cucchini, Franco Noventa, Sabino Iliceto.   

Abstract

Among the so called 'antiphospholipid antibodies', the presence of Lupus Anticoagulant (LA) is associated with thrombosis-related events and defines the antiphospholipid syndrome. The role of anti-cardiolipin (aCL) antibodies and anti-human beta2-glycoprotein I (abeta2GPI) antibodies is less striking. Since the problem of standardization for these tests is far from resolved, we evaluated whether the combination of results (antiphospholipid laboratory profiles) could help to better classify these patients. Over a 6-year period, 618 consecutive subjects (55% of whom had previous documented thrombosis-related events) were referred to our clinic for Antiphospholipid antibody detection. LA was detected according to internationally accepted recommendations. ACL and abeta2GPI antibodies were detected by Enzyme-Linked-Immunosorbent Assay (ELISA). Patients' records were reviewed for the presence of previous thromboembolic events or obstetric complications according to Sapporo's clinical criteria for the diagnosis of antiphospholipid syndrome (APS) and each patient underwent a physical examination. When individual tests were considered in a multivariate analysis which took into account age, gender, the presence of SLE or other autoimmune diseases and established risk factors for venous and arterial thromboembolism, LA (Odds Ratio 4.4, Confidence Interval 1.5-13.3) and abeta2GPI antibodies (Odds Ratio 2.9, Confidence Interval 1.1-7.5) but not aCL antibodies (Odds Ratio 1.2, Confidence Interval 0.5-2.7) were found to be independent risk factors for thrombosis-related events. When antiphospholipid antibody profiles instead of individual test positivity were analyzed in the above mentioned model, triple positivity resulted a strong independent risk factor (Odds Ratio 33.3, Confidence Interval 7.0-157.6), retaining its significance when the association with venous or arterial thromboembolism was considered. Double positivity with negative LA was close to significance for thrombosis-related events (Odds Ratio 2.2, Confidence Interval 1.0-5.2, p=0.056) and highly significant risk factor for obstetric complications (Odds Ratio 10.8, Confidence Interval 2.9-40.8). Other combinations did not reach statistical significance. The mean level of IgG abeta2GPI antibodies was statistically higher in triple positive profile and might account for positive LA. As compared to a single test, the analysis of a complete antiphospholipid antibody profile can better determine patients at risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968401     DOI: 10.1160/TH04-12-0839

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  43 in total

Review 1.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

2.  The "antiphospholipid triangle" in an asymptomatic patient: a case report.

Authors:  Antonella Tufano; Anna Guida; Anna Maria Cerbone; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2010-08-19       Impact factor: 3.397

3.  ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?

Authors:  Natália Mastantuono Nascimento; Sergio Paulo Bydlowski; Rosangela Paula Silva Soares; Danieli Castro Oliveira de Andrade; Eloísa Bonfá; Luciana Parente Costa Seguro; Eduardo Ferreira Borba
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

4.  Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).

Authors:  Matthew Benger; Jasper Vink; Luke Blagdon Snell; Karen Breen
Journal:  BMJ Case Rep       Date:  2019-04-01

5.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

6.  Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: An observational study.

Authors:  A Ç Aykan; T Gökdeniz; M Kalçık; M A Astarcıoğlu; S Gündüz; S Karakoyun; M O Gürsoy; A E Oğuz; E Ertürk; B Çakal; Z Bayram; M Özkan
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

7.  New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Authors:  Savino Sciascia; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

8.  Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases.

Authors:  Simone Saibeni; Maria J Etchevers; Dolors Tassies; Julián Panés; Joan C Reverter; Silvio Danese; Josep M Piqué; Savino Bruno; Maurizio Vecchi; Antonio Gasbarrini; Miquel Sans
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

9.  Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.

Authors:  Natasa Stanisavljevic; L Stojanovich; D Marisavljevic; A Djokovic; V Dopsaj; J Kotur-Stevuljevic; J Martinovic; L Memon; S Radovanovic; B Todic; D Lisulov
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

10.  Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes?

Authors:  Aleksandra Djokovic; Lj Stojanovich; N Stanisavljevic; V Bisenic; S Radovanovic; I Soldatovic; D V Simic
Journal:  Rheumatol Int       Date:  2013-11-15       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.